Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer
- 1 January 2002
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (1) , 70-74
- https://doi.org/10.1016/s0959-8049(01)00336-7
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialPublished by Elsevier ,2000
- Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and IIBritish Journal of Cancer, 1999
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerThe Lancet, 1998
- Experimental solid tumour activity ofN-[2-(dimethylamino)ethyl]-acridine-4-carboxamideCancer Chemotherapy and Pharmacology, 1995
- A Special Role for Amsacrine in the Treatment of Acute LeukemiaCancer Investigation, 1989
- Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamideJournal of Medicinal Chemistry, 1987